Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
Evaluation of brain and spinal cord atrophy by magnetic resonance imaging (MRI) has become an increasingly important component of understanding the multiple sclerosis (MS) disease process. These destructive aspects of the disease develop early in the disease course. A growing body of data links brain and spinal cord atrophy to clinical impairment more closely than can be linked with conventional measures of overt lesions. Thus, irreversible tissue damage may be a key factor leading to disease progression. In this review, the authors present the proposed mechanisms leading to central nervous system (CNS) atrophy. They describe the available MRI-based techniques to measure regional and global atrophy of the brain and spinal cord. They compare the rate of atrophy among MS phenotypes and summarize the emerging data linking atrophy to neurological and neuropsychological impairment. Finally, they discuss the effect of disease-modifying immunotherapies on the rate of CNS atrophy in patients with MS. Future research to clarify the etiology and pathophysiology of brain and spinal cord atrophy should provide new targets for therapeutic development.
Bakshi
Rohit
R
Center for Neurological Imaging, Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. rbakshi@bwh.harvard.edu
Dandamudi
Venkata S R
VS
Neema
Mohit
M
De
Chitradeep
C
Bermel
Robert A
RA
D001284:Atrophy; D001921:Brain / Q000473:pathology*; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008991:Monitoring, Physiologic / Q000379:methods*; D009103:Multiple Sclerosis / Q000473:pathology* / Q000628:therapy; D013116:Spinal Cord / Q000473:pathology*